ChromaDex pens research agreement for study of ‘next-generation niacin’

ChromaDex ‘next-generation niacin’

Natural products firm ChromaDex Corp. has entered into a material transfer agreement with Universite Libre de Bruxelles (ULB), under which ChromaDex will provide ULB with its recently launched Niagen nicotinamide riboside (NR).

Niagen, the first commercially available brand of NR, has the potential to be a “next-generation niacin” (vitamin B3) and become part of the portfolio of B-vitamin ingredients that are included in products serving multi-billion dollar markets such as multi-vitamins, nutraceuticals, weight-loss, energy drinks, sports nutrition, meal replacements, infant formula, food and beverage products, according to a release from the company.

Dr. Oberdan Leo, with the help of ULB researchers Drs. Fabienne Andris, Anthony Rongvaux and Frederic Van Gool, identified the mammalian gene encoding for nicotinamide phosphoribosyl tranferase (Nampt), the rate-limiting enzyme in the biosynthetic pathway linking nicotinamide—a major component of vitamin B3—to the coenzyme NAD. The group  later demonstrated that this biosynthetic pathway plays an important role in lymphocyte development and in the regulation of innate immunity.

In a statement Dr. Leo said, "The discovery that immune activation led to increased expression of Nampt led us to postulate intracellular NAD status may play an important role during an immune response. Exogenous NR has been shown to promote intracellular NAD accumulation and we are therefore thrilled by the possibility to explore, in collaboration with ChromaDex scientists, the effect of NR on the immune system in a series of preclinical models.”

Over the past two years, ChromaDex has built a significant patent portfolio pertaining to NR by separately acquiring patent rights from Cornell University, Dartmouth College and Washington University, with the goal of creating a significant barrier to entry for would-be competitors in the NR market.

Related News

Chromadex CEO: 'If we need to spend millions of dollars to develop an ingredient pipeline, we will do that'

Chromadex CEO: 'If we need to spend millions of dollars to develop an ingredient pipeline, we will do that'

Nicotinamide riboside is found milk and other sources.  ChromaDex's version is a synthesized, bioidentical form.

ChromaDex signs $62 million deal for Niagen, Purenergy ingredients

HPN's N(R) product to support neuroprotection in contact sports - the only commercial product currently available, but more are coming, says Frank Jaksch.

Chromadex CEO: ‘We think Niagen has a much bigger market, like omega-3’

A vitamin found naturally in milk, NR is a more potent version of niacin (vitamin B3) and a precursor to nicotinamide adenine dinucleotide (NAD), increased cellular levels of which have multiple health benefits, says ChromaDex

ChromaDex gears up for launch of next generation niacin ingredient

The fountain of youth? Study suggests vitamin B3 may increase lifespan

The fountain of youth? Study suggests vitamin B3 may increase lifespan ... in worms

Related Products

See more related products